HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


PDUFA VI: FDA Wary Of Industry Proposals With More Metrics

This article was originally published in The Tan Sheet

Executive Summary

Review system proposals could overburden staff, FDA says; formal meeting goals already on tap for changes.

You may also be interested in...

Breakthrough Requests: FDA Adds Quick Screen To Pare Workload

Hope is to quickly reject obviously inadequate designation requests, but few meet criteria for dismissal so far.

PDUFA Negotiations Begin With FDA Seeking Review System Reform

Fee structure changes and process enhancements floated during opening session between industry and agency.

Does PDUFA Need A Haircut? FDA Ponders Trimming Its Responsibilities

Acting Commissioner Ostroff wonders if all aspects of user fee program are delivering maximum added value.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts